In COVID-19 with hypoxemia, 12 vs. 6 mg/d of dexamethasone did not increase days alive without life support

Munch MW, Myatra SN, Vijayaraghavan BK, et al. JAMA. 2021;326:1807-17. 34673895.

Saved in:

Bibliographic Details
Published in:	Annals of internal medicine Vol. 175; no. 3; p. JC33
Main Author:	Jacka, Michael J
Format:	Journal Article
Language:	English
Published:	United States American College of Physicians 01-03-2022
Subjects:	Adult Clinical outcomes Clinical trials COVID-19 COVID-19 - drug therapy Dexamethasone - adverse effects Drug therapy Humans Hypoxia Life expectancy Probability SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Steroids
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Munch MW, Myatra SN, Vijayaraghavan BK, et al. JAMA. 2021;326:1807-17. 34673895.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Commentary-1
ISSN:	0003-4819 1539-3704
DOI:	10.7326/J22-0001